摘要
目的目前精神分裂症的临床诊断缺乏统一的标准。文中研究精神分裂症患者血清中差异miRNA表达谱,为该病的临床诊断提供依据。方法采用Flash TagTMBiotin RNA芯片技术和SAM软件筛选精神分裂症患者与健康受试者血清中差异表达的miRNA,用实时荧光定量逆转录PCR(RT-PCR)进行验证。结果筛选出3个差异表达的miRNA,其中hsa-miR-1281上调,表达倍数变化为1.508 81;hsa-miR-2861、hsa-miR-638下调,表达倍数变化分别为0.641 93和0.516 24。实时定量PCR结果证实,精神分裂症患者较健康受试者hsa-miR-2861与hsa-miR-638表达下调,分别为[(0.037±0.037)vs(3.159±2.761),χ2=4.089,P<0.05]及[(0.006±0.006)vs(0.689±0.314),χ2=4.083,P<0.05],hsa-miR-1281在精神分裂症患者组呈高表达[(1.221±0.041)vs(0.145±0.036),χ2=5.333,P<0.05)。结论精神分裂症患者血清中存在差异表达的miRNA谱,miR-1281、miR-2861和miR-638可作为诊断精神分裂症的一个新的血清标志物。
Objective No uniform standards has been established for the clinical diagnosis of schizophrenia. The article was to investigate the differentially expressed microRNA (miRNA) profile and explore its clinical significance. Methods Differentially expressed miRNAs were screened by FlashTagTM Biotin RNA chips and SAM software in serum of patients with schizophrenia and healthy controls, then the validation was performed by real-time fluorescent quantitative reverse transcription polymerase chain reaction (RT-PCR). Results Three differentially expressed miRNAs were screened, including up-regulated hsa-miR-1281 (fold change = 1. 508 81 ) and two down-regulated miRNAs : hsa-miR-2861 ( fold change = 0. 642) and hsa-miR-638 ( fold change = 0.516). The com- parative analysis of RT-PCR by SPSS 17.0 Kruskal Wallis H Test validated the expression levels of hsa-miR-2861 and hsa-miR-638 in patients with schizophrenia decreased significantly in comparison to healthy controls ( χ2 = 4. 089, χ2 = 4.083, P 〈 0. 001 ). While the expression level of hsa-miR-1281 in patients with schizophrenia was in higher expression level compared with control group (χ2 = 5. 333, P 〈 0.001 ). Conclusion There are differentially expressed miRNA profile in serum of patients with schizophrenia, in which miR-1281, miR-2861 and miR-638 could be new serum markers for diagnosis of schizophrenia.
出处
《医学研究生学报》
CAS
北大核心
2014年第12期1290-1293,共4页
Journal of Medical Postgraduates
基金
四川省教育厅科研项目(11ZB127)